CHAP-XX

CHAP-XX is a preclinical-stage therapeutic candidate being developed by Neuropeutics for the treatment of neurodegenerative diseases characterized by TDP-43 proteinopathy, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Alzheimer's disease. The compound is designed to target and reduce the pathological aggregation of TAR DNA-binding protein 43 (TDP-43), which is a hallmark of these conditions. While the specific modality has not been explicitly disclosed, the 'CHAP' designation suggests a mechanism involving molecular chaperones to prevent or reverse protein misfolding and clumping. The drug is part of a pipeline that includes other TDP-43-targeting agents such as JRMS-22 and HSP-XX.